THE ROLE OF MICROBIAL COMMUNITIES OF AIRWAYS IN PATHOGENESIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
https://doi.org/10.20538/1682-0363-2014-1-153-160
Abstract
This review summarizes the results of studies on the composition of microbial communities in the airways of healthy subjects and in patients with chronic obstructive pulmonary disease. Modern technologies of molecular-genetic identification methods of microorganisms allow to perform a deep analysis of the respiratory microbiom. It is of considerable interest to determine the role of the microbiome in the development of human diseases of the bronchopulmonary system, and to understand the impact of the microbes communities as a course of disease and the important factor for the efficacy of current therapy.
About the Authors
S. V. Fedosenko
Siberian State Medical University, Tomsk
Russian Federation
Fedosenko Sergey V.
Russian Federation
Fedosenko Sergey V.
L. M. Ogorodova
Siberian State Medical University, Tomsk
Russian Federation
Ogorodova Lyudmila M.
Russian Federation
Ogorodova Lyudmila M.
M. A. Karnaushkina
Moscow State Medical and Dental University named after A.I. Yevdokimov, Moscow
Russian Federation
Karnaushkina Mariya A.
Russian Federation
Karnaushkina Mariya A.
Ye. S. Kulikov
Siberian State Medical University, Tomsk
Russian Federation
Kulikov Yevgeny S.
Russian Federation
Kulikov Yevgeny S.
I. A. Deyev
Siberian State Medical University, Tomsk
Russian Federation
Deev Ivan A.
Russian Federation
Deev Ivan A.
N. A. Kirillova
Siberian State Medical University, Tomsk
Russian Federation
Kirillova Nataliya A.
Russian Federation
Kirillova Nataliya A.
References
1. Centers for Disease Control and Prevention. Surveillance Summaries. MMWR 2002. 51 (No. SS-6).
2. Hilty M., Burke C., Pedro H., Cardenas P. et al. Disordered microbial communities in asthmatic airways. PLoS One, 2010, 5 (1):e8578.
3. Beck J.M., Young V.B., Huffnagle G.B. The microbiome of the lung. Transl. Res., 2012, 160 (4), pp. 258–266.
4. Staley J.T., Konopka A. Measurement of in situ activities of nonphotosynthetic microorganisms in aquatic and terrestrial habitats. Annu. Rev. Microbiol., 1985, 39, pp. 321–346.
5. NIH HMP Working Group. The NIH Human Microbiome Project. Genome Res., 2009, 19 (12), pp. 2317–2323.
6. Mirzabeckov A.D., Prokopenko D.V., Chechetkin V.R. Application matrix with immobilized DNA biochips in biology and medicine. Information biomedical technology. Moscow, GEOTAR Honey Publ., 2002, pp. 166–198 (in Russian).
7. Collins, M.D., Walbanks S. Comparative sequence analysis of the 16 S rRNA genes of Lactobacillus miuitus, Lactobacillus rimae and Streptococcus parvulus: proposal for the creation of a new genus Atopobium. FEMS Microbiol Lett., 1992, 95, pp. 235–240.
8. Aas J.A., Paster B.J., Stokes L.N., Olsen I., Dewhirst F.E. Defining the normal bacterial flora of the oral cavity. J. Clin. Microbiol., 2005, 43, pp. 5721–5732.
9. Tunney M.M., Field T.R., Moriarty T.F., Patrick S., Doering G. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med., 2008, 177, pp. 995–1001.
10. Rutgers S.R., Postma D.S., ten Hacken N.H. et al. Ongoing airway inflammation in patients with COPD who do not cur- rently smoke. Thorax., 2000, Jan, 55 (1), pp. 12–18.
11. Barnes P.J. Small airways in COPD. N. Engl. J. Med., 2004, Jun, 24, 350 (26), pp. 2635–2637.
12. Hill A.T, Campbell E.J., Hill S.L. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am. J. Med., 2000, 109, pp. 288–295.
13. Sethi S., Maloney J., Grove L. et al. Airway Inflammation and Bronchial Bacterial Colonization in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med., 2006, May, 1, 173 (9), pp. 991–998.
14. Bilde L., Rud Svenning A., Dollerup J. The cost of treating patients with COPD in Denmark – A population study of COPD patients compared with non-COPD controls. Respir. Med., 2007, 101, pp. 539–546.
15. Sze M.A., Dimitriu P.A., Hayashi S., Elliott W.M., McDonough J.E., Gosselink J.V., Cooper J., Sin D.D., Mohn W.W., James C. Hogg J.C. The Lung Tissue Microbiome in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 10, pp. 1073–1080.
16. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Update 2011. Mode of access: http://www.goldcopd.com/ GuidelineItem.asp?intId=989.
17. Monso E., Ruiz J., Tosell A. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med., 1995, 152, pp. 1316–1320.
18. Sinopalnikov A.I., Maev E.Z. Exacerbation of chronic obstructive pulmonary disease. Modern approaches to treatment. Antibiotics and chemotherapy, 1999, 4, pp. 35–38 (in Russian).
19. Monso E., Rosell A., Bonet G. Risk factors for lower airway colonization in chronic bronchitis. Eur. Respir. J., 1999, 13, pp. 338–342.
20. Sehti S., Evans N., Grant B.J.B., Murphy T.F.N. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. Engl. J. Med., 2002, 347, pp. 465–471.
21. Murphy T.F., Brauer A.L., Eschberger K., Lobbins P., Grove L., Cai X., Sethi S. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2008, Apr. 15, 177 (8), pp. 853–860.
22. Murphy T.F., Brauer A.L., Grant B.J., Sethi S. Moraxella catarrhalis in chronic obstructive pulmonary disease: burden of disease and immune response. Am. J. Respir. Crit. Care Med., 2005, Jul. 15, 172 (2), pp. 195–199.
23. Sehti S., Evans N., Grant B.J.B., Murphy T.F. N. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. Engl. J. Med., 2002, 347, pp. 465–471.
24. Sethi S., Wrona C., Eschberger K., Lobbins P., Cai X., Murphy T.F. Inflammatory profile of new bacterial strainexacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2008, Mar. 1, 177 (5), pp. 491–497.
25. Sethi S., Murphy T.F. Review Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med., 2008, Nov. 27, 359 (22), pp. 2355–2365.
26. Martínez-Solano L., Macia M.D., Fajardo A., Oliver A., Martinez J.L. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin. Infect. Dis., 2008, Dec., 15, 47 (12), pp. 1526–1533.
27. Rakhimova E., Wiehlmann L., Brauer A.L., Sethi S., Murphy T.F., Tümmler B. Pseudomonas aeruginosa population biology in chronic obstructive pulmonary disease. J. Infect. Dis., 2009, Dec., 15, 200 (12), pp. 1928–1935.
28. Wark P., Tooze M., Powell H., Parsons K. Viral and bacterial infection in acute asthma & chronic obstructive pulmonary disease increases the risk of readmission. Respirology, 2013, doi: 10.1111/resp.12099.
Review
For citations:
Fedosenko S.V., Ogorodova L.M., Karnaushkina M.A., Kulikov Ye.S., Deyev I.A., Kirillova N.A. THE ROLE OF MICROBIAL COMMUNITIES OF AIRWAYS IN PATHOGENESIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Bulletin of Siberian Medicine. 2014;13(1):153-160. (In Russ.) https://doi.org/10.20538/1682-0363-2014-1-153-160
Views:
800
Email this article 